Finepoint Capital L.P. 13F annual report
By Rachel Davis
Finepoint Capital L.P. is an investment fund managing more than $269 billion ran by Stacy Vezina. There are currently 17 companies in Mrs. Vezina’s portfolio. The largest investments include Cytokinetics Inc and Acadia Pharmaceuticals Inc, together worth $60.1 billion.
$269 billion Assets Under Management (AUM)
As of 6th February 2024, Finepoint Capital L.P.’s top holding is 431,693 shares of Cytokinetics Inc currently worth over $36 billion and making up 13.4% of the portfolio value.Relative to the number of outstanding shares of Cytokinetics Inc, Finepoint Capital L.P. owns more than approximately 0.1% of the company.In addition, the fund holds 769,653 shares of Acadia Pharmaceuticals Inc worth $24.1 billion, whose value fell approximately 0.1% in the past six months. The third-largest holding is Amicus Therapeutics Inc worth $21.1 billion and the next is Arvinas Inc worth $20.8 billion, with 504,700 shares owned.
Currently, Finepoint Capital L.P.'s portfolio is worth at least $269 billion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Finepoint Capital L.P.
The Finepoint Capital L.P. office and employees reside in Boston, Massachusetts. According to the last 13-F report filed with the SEC, Stacy Vezina serves as the General Counsel at Finepoint Capital L.P..
